Skip to main content
icon for FDA approvals in July
Teknologi·Science

FDA approvals in July

icon for FDA approvals in July
Teknologi·Science

FDA approvals in July

Ended: Jul 31, 2025

Apr 30

Apr 30

May 18

Ended: Jul 31, 2025

Apr 30

Apr 30

May 18

$108,387 Vol.

Jul 31, 2025
Polymarket

$108,387 Vol.

Polymarket

RP1 (BLA)

$78,750 Vol.

No

Blenrep (BLA)

$13,076 Vol.

No

TransCon hGH (sBLA)

$3,355 Vol.

Yes

Aficamten (NDA)

$8,017 Vol.

No

Empaveli (sNDA)

$852 Vol.

Yes

Sepiapterin (NDA)

$3,598 Vol.

Yes

Odronextamab/Ordspono (Resubmitted BLA)

$739 Vol.

No

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate
use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$108,387
Tanggal Berakhir
Jul 31, 2025
Pasar Dibuka
Jul 21, 2025, 7:40 PM ET

Resolver

0x157Ce2d67...
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Hasil diajukan: No

Tidak ada sengketa

Hasil akhir: No

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate
use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$108,387
Tanggal Berakhir
Jul 31, 2025
Pasar Dibuka
Jul 21, 2025, 7:40 PM ET

Resolver

0x157Ce2d67...
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for the listed drug by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the month, the market will resolve to "No" immediately. If the listed drug is approved before the end of the month, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Hasil diajukan: No

Tidak ada sengketa

Hasil akhir: No

Hati-hati dengan link eksternal.

Pertanyaan yang Sering Diajukan

"FDA approvals in July" adalah pasar prediksi di Polymarket dengan 7 hasil yang mungkin di mana trader membeli dan menjual saham berdasarkan apa yang mereka yakini akan terjadi. Hasil terdepan saat ini adalah "TransCon hGH (sBLA)" di 100%, diikuti oleh "Empaveli (sNDA)" di 100%. Harga mencerminkan probabilitas crowd-sourced real-time. Misalnya, saham yang dihargai 100¢ menyiratkan bahwa pasar secara kolektif memberikan peluang 100% pada hasil tersebut. Peluang ini bergeser terus-menerus saat trader bereaksi terhadap perkembangan dan informasi baru. Saham dengan hasil yang benar bisa ditukarkan seharga $1 setiap saham saat pasar diselesaikan.

Per hari ini, "FDA approvals in July" telah menghasilkan $108.4K dalam total volume trading sejak pasar diluncurkan pada Jul 21, 2025. Tingkat aktivitas trading ini mencerminkan keterlibatan kuat dari komunitas Polymarket dan membantu memastikan bahwa peluang saat ini diinformasikan oleh kumpulan besar peserta pasar. Kamu bisa melacak pergerakan harga langsung dan trading di hasil apa pun langsung di halaman ini.

Untuk trading di "FDA approvals in July," jelajahi 7 hasil yang tersedia di halaman ini. Setiap hasil menampilkan harga saat ini yang mewakili probabilitas tersirat pasar. Untuk mengambil posisi, pilih hasil yang menurutmu paling mungkin, pilih "Ya" untuk mendukungnya atau "Tidak" untuk menentangnya, masukkan jumlahmu, dan klik "Trade." Jika hasil pilihanmu benar saat pasar diselesaikan, saham "Ya" kamu membayar $1 masing-masing. Jika salah, mereka membayar $0. Kamu juga bisa menjual sahammu kapan saja sebelum resolusi jika kamu ingin mengamankan keuntungan atau memotong kerugian.

Unggulan saat ini untuk "FDA approvals in July" adalah "TransCon hGH (sBLA)" di 100%, yang berarti pasar memberikan peluang 100% pada hasil tersebut. Hasil terdekat berikutnya adalah "Empaveli (sNDA)" di 100%. Peluang ini diperbarui secara real-time saat trader membeli dan menjual saham, sehingga mencerminkan pandangan kolektif terbaru tentang apa yang paling mungkin terjadi. Cek kembali secara rutin atau tandai halaman ini untuk mengikuti bagaimana peluang bergeser saat informasi baru muncul.

Aturan resolusi untuk "FDA approvals in July" mendefinisikan dengan tepat apa yang harus terjadi agar setiap hasil dinyatakan sebagai pemenang — termasuk sumber data resmi yang digunakan untuk menentukan hasilnya. Kamu bisa meninjau kriteria resolusi lengkap di bagian "Aturan" di halaman ini di atas komentar. Kami menyarankan membaca aturan dengan cermat sebelum trading, karena mereka menentukan kondisi tepat, kasus khusus, dan sumber yang mengatur bagaimana pasar ini diselesaikan.